DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.932
-0.008 (-0.412%)
As of 10:55AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.940
Open1.920
Bid1.930 x 600
Ask1.950 x 2100
Day's Range1.851 - 1.950
52 Week Range0.740 - 2.170
Volume135,306
Avg. Volume459,783
Market Cap284M
Beta2.10
PE Ratio (TTM)-7.43
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    ETFs with exposure to DURECT Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
    Capital Cube15 days ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 4.32 million, Net Earnings of USD -9.93 million. Gross margins widened from 71.08% to 78.61% compared to the same period last year, operating (EBITDA) margins now -214.24% from -265.79%. Change in operating cash ... Read more (Read more...)

  • Zacks Small Cap Research16 days ago

    DURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLC

    Pursuant to the agreement, DURECT has assigned certain of its U.S. patent rights to Indivior. This assignment may provide further intellectual property protection for RBP-7000, Indivior's investigational once-monthly injectable risperidone product for the treatment of schizophrenia.  Indivior has submitted a New Drug Application (NDA) for RBP-7000 to the U.S. Food and Drug Administration (FDA).

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 DURECT Corp Earnings Call

  • Zacks Small Cap Research2 months ago

    DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States

    On May 8, 2017, Durect (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States Durect’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. Under the terms of the agreement, Sandoz will make an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales based milestones, as well as a tiered double digit royalty on product sales in the United States. The $43 million could be received when Durect resubmits the NDA and get approval for Posimir which could be done in 1Q18.

  • Associated Press2 months ago

    Durect reports 2Q loss

    On a per-share basis, the Cupertino, California-based company said it had a loss of 7 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • Capital Cube3 months ago

    ETFs with exposure to DURECT Corp. : July 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube5 months ago

    ETFs with exposure to DURECT Corp. : May 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of DRRX earnings conference call or presentation 10-May-17 8:30pm GMT

    Q1 2017 DURECT Corp Earnings Call

  • Capital Cube5 months ago

    ETFs with exposure to DURECT Corp. : May 15, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
    Capital Cube5 months ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

    Categories: Yahoo FinanceGet free summary analysis DURECT Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of DURECT Corp. – Zogenix, Inc., Impax Laboratories, Inc., Johnson & Johnson, Pfizer Inc., Pacira Pharmaceuticals, Inc., Heron Therapeutics Inc, Eli Lilly and Company and Corium International, Inc. (ZGNX-US, IPXL-US, ... Read more (Read more...)

  • Associated Press5 months ago

    Durect reports 1Q loss

    The Cupertino, California-based company said it had a loss of 6 cents per share. The specialty pharmaceutical company posted revenue of $4.6 million in the period. In the final minutes of trading on Wednesday, ...

  • Zacks Small Cap Research5 months ago

    DURECT(DRRX): A $293 Million Deal with Sandoz for POSIMIR® in the United States

    Earlier today (May 8, 2017), Durect  Corporation (DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery. Under the terms of the agreement, Sandoz will make an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales based milestones, as well as a tiered double digit royalty on product sales in the United States.

  • Capital Cube6 months ago

    ETFs with exposure to DURECT Corp. : April 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Reuters6 months ago

    NASH: The next untapped pharma market gives investors many options

    Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver ...

  • Capital Cube7 months ago

    ETFs with exposure to DURECT Corp. : March 27, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube7 months ago

    DURECT Corp. :DRRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis DURECT Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of DURECT Corp. – Pain Therapeutics, Inc., Zogenix, Inc., Impax Laboratories, Inc., Johnson & Johnson, Pfizer Inc., Pacira Pharmaceuticals, Inc., Heron Therapeutics Inc, Eli Lilly and Company and Corium International, ... Read more (Read more...)

  • Associated Press7 months ago

    Durect reports 4Q loss

    On a per-share basis, the Cupertino, California-based company said it had a loss of 6 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • Zacks Small Cap Research8 months ago

    DRRX: Update on DUR-928 Development Program

    By Grant Zeng, CFA NASDAQ:DRRX Among Durect’s (NASDAQ:DRRX) multiple candidates, DUR-928 may be the most promising one in our view because this compound has the potential to target multiple indications ...

  • How DURECT Corporation (DRRX) Stacks Up Against Its Peers
    Insider Monkey10 months ago

    How DURECT Corporation (DRRX) Stacks Up Against Its Peers

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • Capital Cube10 months ago

    ETFs with exposure to DURECT Corp. : December 9, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube11 months ago

    ETF’s with exposure to DURECT Corp. : November 3, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to DURECT Corp. Here are 5 ETF’s with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 2, 2016
    Capital Cubelast year

    DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 2, 2016

    Categories: Yahoo Finance Get free summary analysis DURECT Corp. reports financial results for the quarter ended September 30, 2016. We analyze the earnings along side the following peers of DURECT Corp. – Pain Therapeutics, Inc., Johnson & Johnson and Eli Lilly and Company (PTIE-US, JNJ-US and LLY-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • Zacks Small Cap Researchlast year

    Durect (DRRX) Exited Third Quarter with Strong Balance Sheet

    By Grant Zeng, CFA NASDAQ:DRRX Durect Exited Third Quarter with Strong Balance Sheet On October 31, Durect (NASDAQ:DRRX) announced its financial results for the third quarter of 2016 ended September 30. ...